Epidemiology and costs of diabetes mellitus in Switzerland: An analysis of health care claims data, 2006 and 2011

BMC Endocrine Disorders

Volumn 14, Issue , 2014, Pages

  Huber, Carola A ^a   Schwenkglenks, Matthias ^b   Rapold, Roland ^a   Reich, Oliver ^a  

^a Helsana Group   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Costs; Diabetes; Incidence; Mortality; Prevalence

Indexed keywords

ADULT; AGE; ARTICLE; DIABETES MELLITUS; FEMALE; GENDER; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; POPULATION RESEARCH; PRESCRIPTION; PREVALENCE; RESOURCE ALLOCATION; SWITZERLAND; TREND STUDY; COST OF ILLNESS; DIABETES MELLITUS, TYPE 2; ECONOMICS; EPIDEMIOLOGY; FOLLOW UP; HEALTH CARE DELIVERY; LONGITUDINAL STUDY; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE;

ADULT; COST OF ILLNESS; DELIVERY OF HEALTH CARE; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; INSURANCE, HEALTH; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; SWITZERLAND;

EID: 84902164520     PISSN: None     EISSN: 14726823     Source Type: Journal    
DOI: 10.1186/1472-6823-14-44     Document Type: Article

References (32)

1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011, 94:311-321. 10.1016/j.diabres.2011.10.029, 22079683.
2. Struijs JN, Baan CA, Schellevis FG, Westert GP, van den Bos GA. Comorbidity in patients with diabetes mellitus: impact on medical health care utilization. BMC Health Serv Res 2006, 6:84. 10.1186/1472-6963-6-84, 1534031, 16820048.
3. Mo F, Pogany LM, Li FC, Morrison H. Prevalence of diabetes and cardiovascular comorbidity in the Canadian Community Health Survey 2002-2003. Scientific World Journal 2006, 6:96-105.
4. Roglic G, Unwin N, Bennett PH, Mathers C, Tuomilehto J, Nag S, Connolly V, King H. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 2005, 28:2130-2135. 10.2337/diacare.28.9.2130, 16123478.
5. Lipscombe LL, Hux JE. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: a population-based study. Lancet 2007, 369:750-756. 10.1016/S0140-6736(07)60361-4, 17336651.
6. Köster I, Huppertz E, Hauner H, Schubert I. Direct costs of diabetes mellitus in Germany - CoDiM 2000-2007. Exp Clin Endocrinol Diabetes 2011, 119:377-385. 10.1055/s-0030-1269847, 21264804.
7. Jönsson B, . CODE-2 Advisory Board Revealing the cost of Type II diabetes in Europe. Diabetologia 2002, 45:S5-S12. 10.1007/s00125-002-0858-x, 12136405, CODE-2 Advisory Board.
8. American Diabetes Association Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008, 31:596-615. American Diabetes Association.
9. Kaiser A, Vollenweider P, Waeber G, Marques-Vidal P. Prevalence, awareness and treatment of type 2 diabetes mellitus in Switzerland: the CoLaus study. Diabet Med 2012, 29:190-197. 10.1111/j.1464-5491.2011.03422.x, 21883431.
10. Bopp M, Zellweger U, Faeh D. Routine data sources challenge international diabetes Federation extrapolations of national diabetes prevalence in Switzerland. Diabetes Care 2011, 34:2387-2389. 10.2337/dc11-0157, 3198273, 21926288.
11. Rizza A, Kaplan V, Senn O, Rosemann T, Bhend H, Tandjung R, . FIRE study group Age- and gender-related prevalence of multimorbidity in primary care: the swiss fire project. BMC Fam Pract 2012, 13:113. 10.1186/1471-2296-13-113, 3557138, 23181753, FIRE study group.
12. Schmitt-Koopmann I, Schwenkglenks M, Spinas GA, Szucs TD. Direct medical costs of type 2 diabetes and its complications in Switzerland. Eur J Public Health 2004, 14:3-9.
13. Weber C, Schneider B, Lodwig V, Holm MV, Neeser K. Cost impact of blood glucose self-monitoring on complications of type 2 diabetes: a Swiss perspective (ROSSO study No.11). Swiss Med Wkly 2007, 137:545-550.
14. O'Shea M, Teeling M, Bennett K. The prevalence and ingredient cost of chronic comorbidity in the Irish elderly population with medication treated type 2 diabetes: a retrospective cross-sectional study using a national pharmacy claims database. BMC Health Serv Res 2013, 13:23. 10.1186/1472-6963-13-23, 3554499, 23324517.
15. WHO Collaborating Centre for Drug Statistics Methodology Guidelines for ATC classification and DDD assignment 2011 2010, Oslo: WHO, WHO Collaborating Centre for Drug Statistics Methodology.
16. Lamers LM, van Vliet RC. The Pharmacy-based Cost Group model: validating and adjusting the classification of medications for chronic conditions to the Dutch situation. Health Policy 2004, 68:113-121. 10.1016/j.healthpol.2003.09.001, 15033558.
17. Tu K, Manuel D, Lam K, Kavanagh D, Mitiku TF, Guo H. Diabetics can be identified in an electronic medical record using laboratory tests and prescriptions. J Clin Epidemiol 2011, 64:431-435. 10.1016/j.jclinepi.2010.04.007, 20638237.
18. Common Institution of Health Insurance Law 2012. Gemeinsame Einrichtung Krankenversicherungsgesetz, KVG, [http://www.kvg.org/de/risikoausgleich-_content---1--1047.html].
19. Swiss Federal Office of Statistic [http://www.bfs.admin.ch/bfs/portal/de/index/themen/01/02/blank/key/alter/gesamt.html].
20. Wilke T, Ahrendt P, Schwartz D, Linder R, Ahrens S, Verheyen F. Incidence and prevalence of type 2 diabetes mellitus in Germany: an analysis based on 5.43 million patients. Dtsch Med Wochenschr 2013, 138:69-75.
21. Tabaei BP, Chamany S, Driver CR, Kerker B, Silver L. Incidence of self-reported diabetes in New York City, 2002, 2004, and 2008. Prev Chronic Dis 2012, 9:E114. 3457762, 22698175.
22. Monesi L, Baviera M, Marzona I, Avanzini F, Monesi G, Nobili A, Tettamanti M, Cortesi L, Riva E, Fortino I, Bortolotti A, Fontana G, Merlino L, Roncaglioni MC. Prevalence, incidence and mortality of diagnosed diabetes: evidence from an Italian population-based study. Diabet Med 2012, 29:385-392. 10.1111/j.1464-5491.2011.03446.x, 21913971.
23. Marques-Vidal P, Bovet P, Paccaud F, Chiolero A. Changes of overweight and obesity in the adult Swiss population according to educational level, from 1992 to 2007. BMC Public Health 2010, 10:87. 10.1186/1471-2458-10-87, 2831837, 20170554.
24. Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, Li H, Li H, Jiang Y, An Y, Shuai Y, Zhang B, Zhang J, Thompson TJ, Gerzoff RB, Roglic G, Hu Y, Bennett PH. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008, 371:1783-1789. 10.1016/S0140-6736(08)60766-7, 18502303.
25. Gregg EW, Gu Q, Cheng YJ, Narayan KM, Cowie CC. Mortality trends in men and women with diabetes, 1971 to 2000. Ann Intern Med 2007, 147:149-155. 10.7326/0003-4819-147-3-200708070-00167, 17576993.
26. Preis SR, Hwang SJ, Coady S, Pencina MJ, D'Agostino RB, Savage PJ, Levy D, Fox CS. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 2009, 119:1728-1735. 10.1161/CIRCULATIONAHA.108.829176, 2789419, 19307472.
27. Dall TM, Zhang Y, Chen YJ, Quick WW, Yang WG, Fogli J. The economic burden of diabetes. Health Aff (Millwood) 2010, 29:297-303. 10.1377/hlthaff.2009.0155, 20075080.
28. Kanavos P, van den Aardweg S, Schurer W. Diabetes expenditures, burden of disease and management in 5 EU countries. LSE Health, London School of Economics, [http://www2.lse.ac.uk/LSEHealthAndSocialCare/research/LSEHealth/MTRG/LSEDiabetesReport26Jan2012.pdf].
29. Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, Shaw J, Nichols G. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010, 87:293-301. 10.1016/j.diabres.2010.01.026, 20171754.
30. Leon DA. Trends in European life expectancy: a salutary view. Int J Epidemiol 2011, 40:271-277. 10.1093/ije/dyr061, 21415000.
31. Coleman K, Austin BT, Brach C, Wagner EH. Evidence on the Chronic Care Model in the new millennium. Health Aff (Millwood) 2009, 28:75-85. 10.1377/hlthaff.28.1.75, 19124857.
32. Lindström J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemiö K, Hämäläinen H, Härkönen P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Paturi M, Sundvall J, Valle TT, Uusitupa M, Tuomilehto J, . Finnish Diabetes Prevention Study Group Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006, 368:1673-1679. 10.1016/S0140-6736(06)69701-8, 17098085, Finnish Diabetes Prevention Study Group.